Used in the treatment of hematologic disorders such as atypical hemolytic uremic syndrome (aHUS), where it inhibits the lectin pathway of the complement system. By targeting MASP-2, it prevents inflammation and endothelial damage associated with uncontrolled complement activation. Investigated in transplant-related complications and other complement-mediated diseases due to its role in modulating immune response without broad immunosuppression.